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Next-generation sequencing of circulating tumor DNA to
predict recurrence in triple-negative breast cancer patients with
residual disease after neoadjuvant chemotherapy
Yu-Hsiang Chen 1, Bradley A. Hancock2, Jeffrey P. Solzak2, Dumitru Brinza3, Charles Scafe3, Kathy D. Miller4,5 and Milan Radovich1,2,5,6
Next-generation sequencing to detect circulating tumor DNA is a minimally invasive method for tumor genotyping and monitoring
therapeutic response. The majority of studies have focused on detecting circulating tumor DNA from patients with metastatic disease.
Herein, we tested whether circulating tumor DNA could be used as a biomarker to predict relapse in triple-negative breast cancer
patients with residual disease after neoadjuvant chemotherapy. In this study, we analyzed samples from 38 early-stage triple-negative
breast cancer patients with matched tumor, blood, and plasma. Extracted DNA underwent library preparation and amplification using
the Oncomine Research Panel consisting of 134 cancer genes, followed by high-coverage sequencing and bioinformatics. We
detected high-quality somatic mutations from primary tumors in 33 of 38 patients. TP53 mutations were the most prevalent (82%)
followed by PIK3CA (16%). Of the 33 patients who had a mutation identified in their primary tumor, we were able to detect circulating
tumor DNA mutations in the plasma of four patients (three TP53 mutations, one AKT1 mutation, one CDKN2A mutation). All four
patients had recurrence of their disease (100% specificity), but sensitivity was limited to detecting only 4 of 13 patients who clinically
relapsed (31% sensitivity). Notably, all four patients had a rapid recurrence (0.3, 4.0, 5.3, and 8.9 months). Patients with detectable
circulating tumor DNA had an inferior disease free survival (p < 0.0001; median disease-free survival: 4.6 mos. vs. not reached; hazard
ratio = 12.6, 95% confidence interval: 3.06–52.2). Our study shows that next-generation circulating tumor DNA sequencing of triple-
negative breast cancer patients with residual disease after neoadjuvant chemotherapy can predict recurrence with high specificity,
but moderate sensitivity. For those patients where circulating tumor DNA is detected, recurrence is rapid.
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INTRODUCTION
Triple-negative breast cancer (TNBC) is defined by the absence of
estrogen-receptor (ER), progesterone-receptor (PR), and human
epidermal growth factor receptor 2 (HER2) over-expression.1–4
While TNBC comprises a minority of breast cancer cases (15–20%),
it results in a disproportionally higher rate of mortality. Compared
to ER- and HER2-postive disease, TNBCs have a higher incidence of
visceral metastasis, a higher likelihood of relapse within the first 3
years after chemotherapy and surgery, and a shorter overall
survival (OS) after the onset of metastatic disease.5,6
A significant proportion of patients with TNBC are treated with
neoadjuvant chemotherapy. A stark dichotomy exists in outcome
based on response to neoadjuvant therapy. Approximately, a third
of patients will achieve a pathologic complete response (pCR), and
go on to have a favorable OS outcome (94% at 3 years). In
contradistinction, two-thirds of patients have residual disease after
neoadjuvant chemotherapy and are at a high risk of relapse
leading to an inferior OS (68% at 3 years).7 Methods that can
detect the presence of tumor material in the circulation of patients
who are technically “disease-free” after neoadjuvant chemother-
apy and surgery may be used to predict those patients whose
disease will recur, and further help to determine, which patients
may need additional therapy.
An emerging method for non-invasive cancer detection is the
analysis of circulating tumor DNA (ctDNA), also known as “liquid
biopsies”. ctDNA is released into the circulation from the apoptosis
or necrosis of tumor tissue, or from circulating tumor cells (CTCs)
present in blood.8,9 It has been demonstrated that ctDNA can be
detected in many types of cancer, including: breast,10–14
prostate,15 gastric,16 and others.8 The fraction of ctDNA compared
to total cell-free DNA, can be quite small, in many cases <1%.17–19
Highly sensitive next-generation sequencing techniques though,
can be used to detect low amounts of ctDNA. Herein, using
plasma samples from a completed Phase II clinical trial of TNBC
patients with residual disease after neoadjuvant chemotherapy,
we applied next-generation DNA sequencing to determine if
detection of ctDNA can be used as a predictor of relapse in this
high-risk patient population.
RESULTS
Patient and sample selection
One-hundred thirty-five patients were enrolled on the BRE09-146
clinical trial. Patient characteristics, including: median age, race,
neoadjuvant chemotherapy, radiation therapy, median residual
lymph node positivity (LN+), and median residual cancer burden
(RCB) are detailed in Table 1. All patients received multiple agent
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neoadjuvant chemotherapy, with the vast majority receiving a
combination of anthracycline, cyclophosphamide, and paclitaxel,
followed by surgery and radiotherapy (Table 1). TNBC patients
who completed neoadjuvant therapy and had significant residual
disease were randomized to either cisplatin monotherapy or the
combination of cisplastin plus rucaparib (Fig. 1) (See methods for
details). Plasma samples used for the analysis of ctDNA were only
collected in patients enrolled in the combination arm (Fig. 1).
Details of patient selection included in this study are outlined in
the Consolidated Standards for Reporting Trials (CONSORT)
diagram (Fig. 2). In total, 38 patients with matched tumor tissue,
blood, and at least one plasma sample were successfully
sequenced (Fig. 2).
Identification of somatic mutations in the primary tumors
We first identified somatic mutations present in the primary tumor
by identifying variants from tumor sequencing that were not
present in the matched normal blood. Of the 38 patients described
above, we successfully identified at least one somatic mutation in
87% of patients (33 of 38; Fig. 3), and two or more somatic
mutations in 55% of patients (21 of 38; Fig. 3). Among those who
had somatic mutation(s) identified, 31 patients had TP53 mutations
(33 TP53 mutations in total; two patients had dual TP53 mutations).
Ten out of 38 patients carried genetic alterations in the genes
involved in PI3K signaling pathway. Among those, PIK3CA was the
most common gene with genetic alterations (six patients), followed
by AKT1 (two patients), PIK3R1, and PTEN (one patient each). The
high-rate of TP53 and PI3K mutations is congruent with published
data from the The Cancer Genome Atlas (TCGA),20 which observed
the same pattern in TNBC tumors.
Detection of somatic mutations (ctDNA) in matched plasma
samples
We then searched for the somatic mutations identified from the
primary tumors in the matched plasma samples. Of the 33 patients
who had a somatic mutation identified in their primary tumor, we
were able to detect somatic mutations in the plasma of four patients
(three TP53 mutations, one AKT1 mutation, and one CDKN2A
mutation). All four patients had recurrence of their disease (100%
specificity), but sensitivity was limited to detecting only 4 of 13
patients who relapsed (31% sensitivity). Figure 4 details the time-
course of the mutational allele frequency for these four patients. In
patient 146-0005 (Fig. 4a), a TP53 mutation (Chr17:7578492, C to T)
was detected in timepoint 2 and 4 plasma samples. A similar pattern
(timepoint 1 and 4) was observed in patient 146-0013 who had a
different TP53 mutation (Chr17:7574003, G to A) and a CDKN2A
mutation (Chr9:21974792) (Fig. 4b). We were also able to detect
somatic mutations in plasma samples from the other two patients
who had only one timepoint plasma sample available (146-0102,
AKT1 mutation, Chr14:105246551, C to T; 146-0112, TP53 mutation,
Chr17:7578203, C to T) (Fig. 4c, d). All mutations were located in
Table 1. Clinical characteristics of patients enrolled on the BRE09-146
clinical trial
BRE09-146 Arm A
cisplatin
(n= 65)
Arm B cisplatin
+ rucaparib
(n= 70)
Subjects from
arm B for this
study (n= 38)
Median age 48 (27–69) 47 (21–75) 47 (21–66)
Race
a. African American 20.0% 18.6% 13.2%
b. White 75.4% 72.9% 73.7%
c. Asian 1.5% 4.3% 7.9%
d. Others 3.1% 4.3% 5.3%
Neoadjuvant chemotherapy
a. Anthracycline 89.2% 88.6% 92.1%
b. Cyclophosphamide 95.4% 90.0% 92.1%
c. Taxane 95.4% 92.9% 92.1%
d. Carboplatin 1.5% 10.0% 10.5%
e. Unknown 3.1% 2.9% 0%
Radiation therapy 87.7% 85.7% 84.2%
Median residual lymph
node positivity (LN+)
1 (0–15) 1 (0–38) 1 (0–38)
Median residual cancer
burden
2.6 (0–5.0) 2.7 (0–5.3) 3.1 (0–5.3)
Fig. 1 Trial schema for BRE09-146.BRE09-146 was a Phase II clinical trial to evaluate 2-year disease-free survival (DFS) in TNBC patients, treated
with either Cisplatin (Arm A) or Cisplatin in combination with PARP inhibitor Rucaparib (Arm B) after neoadjuvant chemotherapy. Tumor
tissue, whole blood, and plasma from four time points after surgery were collected as indicated. In this trial, plasma samples were collected
only in Arm B of (the area enclosed by the red rectangle). Plasma samples were collected at four timepoints: Cycles 1 and 2 of the combination
phase, and during weeks 1 and 5 of the maintenance phase
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exonic regions. Interestingly, all four patients had a rapid
recurrence: average of 4.6 months (0.3, 4.0, 5.3, and 8.9 months;
Fig. 4). The lead time of detection of the mutation in the plasma to
clinical recurrence ranged from 0.07 to 8.87 months (Fig. 4). A
Kaplan–Meier plot demonstrates that the patients who had ctDNA
detected in their plasma, had a significantly inferior disease-
free survival (DFS) compared to patients where ctDNA was
not detected (p < 0.0001, median DFS: 4.6 mos. vs. not reached
(NR); hazard ratio (HR) = 12.6, 95% confidence interval (CI):
3.06–52.2) (Fig. 5). In multivariate Cox regression analysis, with
the addition of RCB and number of positive lymph nodes as
covariates, the detection of ctDNA remained independently
associated with inferior DFS (p = 0.011, median DFS: 4.6 mos. vs.
NR; HR = 8.6, 95% CI: 1.6–45.7).
We were also interested in whether subclonal mutational
evolution occurred after chemotherapy, generating new muta-
tions (not present in the primary tumor) that could be detected in
the plasma. To examine this, we analyzed the sequencing data for
mutations which were exclusively present in the plasma samples
from all 38 patients, no matter who had disease recurrence or not.
This analysis did not identify any de novo mutations exclusively in
the plasma, suggesting that only mutations first identified in the
primary tumor were detectable in the plasma.
DISCUSSION
TNBC patients who do not achieve a pCR to neoadjuvant
chemotherapy are at a high-risk of recurrence from their disease.
Unfortunately, there is no FDA approved standard-of-care for this
post-neoadjuvant setting. However, reported results from the
CREATE-X trial (presented at 2015 San Antonio Breast Cancer
Symposium) demonstrated an improvementin 2-year DFS and OS
with the use of post-neoadjuvant Capecitabine for women with
HER2-negative breast cancer with residual disease after neoadjuvant
chemotherapy.21 A subgroup analysis revealed an improved benefit
for TNBC patients.21 Given the clinical scenario, determining those
patients who will relapse using methods that can detect the
presence of tumor material, even when the patient is technically
“disease-free” after surgery, can help predict which patients will recur,
and potentially design therapeutic strategies for this population.
Although tissue biopsy remains the standard approach for determin-
ing the presence of tumor, the so-called “liquid biopsy” using ctDNA
is emerging as a complimentary method. Because somatic mutations
provide intrinsic specificity for nucleic acid material derived from
tumor tissue, the presence of ctDNA implies the presence of disease.
In the evolving realm of circulating biomarkers, a recent study
suggests that ctDNA may confer the highest sensitivity. Dawson
et al.13 compared the use of circulating antigen 15-3, CTCs and ctDNA
for blood-based detection, and demonstrated that the measurement
of ctDNA possessed the highest sensitivity for monitoring metastatic
breast cancer. While the vast majority of ctDNA studies have focused
on patients with metastatic disease, in this study we focused on
patients who are in the curative setting. The patients in our cohort
are disease free by standard clinical assessment, but are known to be
at a high-risk of relapse.
In our study, we searched for somatic mutations in plasma-
sequencing data that were first identified in the matched primary
tumor. Congruent with published studies of genomic sequencing
of TNBCs, we observed a high-rate of TP53 and PI3K pathway
mutations.20 Of 33 evaluable patients, 13 had a clinical relapse,
and of those, we were able to detect ctDNA in 4. Of interest, all
four of these patients had a rapid recurrence, ranging from
0.3 months—8.9 months. Our lead-time from the first-detection of
ctDNA to clinical recurrence ranged from 0.07 months—
8.87 months. We were unable to detect ctDNA in patients with
distant recurrence. Further, we were unable to detect ctDNA in
five patients who had a recurrence in <12 months. While all
patients in which ctDNA was observed did have a rapid
recurrence, the low sensitivity to detect distant, and in some
cases rapid recurrence, highlights its limitations. Because the
Fig. 2 CONSORT diagram. There were 135 patients enrolled in BRE09-146. In this study, we focused on 70 patients from Arm B. In Arm B, 27
patients did not have matched tumor tissue, whole blood, and at least one plasma collection and were excluded from this study leaving an N
= 43. A further five patients were removed due to the inability to successfully create a plasma DNA library. In total, 38 patients reached the
criteria for analysis
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ability to detect ctDNA is proportional to the number of mutated
molecules in the circulation; disease burden, and the volume of
plasma that is sampled are important factors that regulate
sensitivity. Our study represents a “worst-case scenario” in which
there is no detectable disease burden at enrollment, and only 1
mL of plasma in which to perform our studies. Even in this setting,
we were able to detect some patients with rapid recurrence. Given
the retrospective nature of our study with a limited sample size,
however, a prospective trial to prove clinical utility is well
warranted.
A pivotal study by Garcia-Murillas et al.14 in a cohort of early
breast cancer patients demonstrated that detection of ctDNA
showed a similar pattern of rapid recurrence. A similar study by
Olsson et al. showed that serial ctDNA sampling in patients with
primary breast cancer can reach an average lead time of
11 months before the occurrence of metastatic disease.22 Key
differences between our studies and theirs is the specific
enrichment of a TNBC population in our study, and our use of
next-generation sequencing vs. digital-droplet PCR (ddPCR) for
ctDNA detection. While ddPCR has increased sensitivity, it requires
the generation of patient-specific custom assays, thus next-
generation sequencing has the advantage of being more
generalizable for the application of ctDNA detection to a breast
cancer population. Lastly, another study by Riva et al.,23 the
investigators were unable to detect ctDNA in TNBC patients after
surgery using ddPCR. This observation along with ours highlights
the importance of serial sampling after surgery.
In conclusion, next-generation ctDNA-sequencing of TNBC
patients after neoadjuvant chemotherapy and surgery can detect
rapid-recurrence but sensitivity to detect distant recurrence is
limited. Further studies that can capitalize on strategies to increase
sensitivity are well warranted. Indeed, novel extraction methodol-
ogies; sequencing chemistries that attempt to provide increased
enrichment of mutated DNA molecules (i.e., CAPP-Seq24); sensitive
nucleic acid detection using CRISPR-Cas13a25 along with iso-
thermal amplification; or the combination of ctDNA with other
blood-based biomarkers such as miRNA, lncRNA, or exosomal
protein;26 are all further avenues of exploration.
PATIENTS AND METHODS
Clinical trial and correlative samples
BRE09-146 was a prospective, multi-site, Phase II clinical trial of Cisplatin +
PARP inhibition in TNBC patients who have residual disease after
Fig. 3 Somatic mutations identified from sequencing of tumor tissues. Among the 38 patients in our study, 33 of them had at least one
somatic mutation identified (87%); 21 of them had two or more somatic mutations (55%). TP53 mutations were the most prevalent in this
study, followed by PIK3CA pathway mutations. Notably, there were 14 different mutations exclusively present in individual patients,
representing the genomic heterogeneity of TNBC patients
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neoadjuvant chemotherapy. Eligibility criteria required residual disease,
defined as either: (i) residual tumor >2 cm in the breast; (ii) lymph node
involvement; or (iii) RCB classification of II or III. Eligible patients were then
randomized either to Cisplatin for four cycles or Cisplatin plus the PARP
inhibitor Rucaparib for four cycles followed by maintenance Rucaparib for
24 weeks (Fig. 1). Patient were enrolled on trial from March 2010 to May
2013. BRE09-146 is registered on ClinicalTrials.gov (https://clinicaltrials.gov/
ct2/show/study/NCT01074970). For correlative analyses, clinical sites sub-
mitted tumor biopsies from the time of diagnosis, tumor from residual
disease at the time of surgery, as well as whole blood prior to treatment.
From the combination arm only (Cisplatin + Rucaparib), plasma samples that
were originally collected for pharmacokinetic analyses, were obtained at four
pre-defined timepoints: Cycles 1 and 2 of the combination phase, and during
Weeks 1 and 5 of the maintenance phase (detailed in Fig. 1). For this
correlative study of ctDNA, each evaluable patient had to have at least one
tumor sample (with 60% or greater tumor cellularity), one whole blood
sample, and one plasma sample submitted. Tumor DNA was isolated from
formalin-fixed paraffin embedded (FFPE) tissue using the Qiagen AllPrep
DNA/RNA FFPE kit. Whole blood was isolated using AutogenFlex Star
instrument and the Flexigene AGF3000 blood kit at the Indiana Clinical and
Translational Sciences Institute Specimen Storage Facility (ICTSI-SSF). Plasma
DNA was isolated from 1ml of plasma using the Qiagen QIAamp Circulating
Nucleic Acid Kit. All DNA samples were quantified using the Qubit dsDNA HS
Assay Kit (Life Technologies). The trial and correlative studies were approved
by the Indiana University Institutional Review Board (IRB); patients provided
written informed consent prior to study entry including consent for blood
samples for genomic analysis. The study was conducted in accordance with
appropriate protocols established by Indiana University.
Library preparation and sequencing
DNA samples from each tumor, blood, and plasma sample underwent the
same procedure for library preparation. DNA samples were amplified using a
highly-multiplexed polymerase chain reaction (PCR) that amplifies 134 genes
that are well-known to be mutated in cancer (Ion Ampliseq Oncomine
Research Panel) (see Supplementary Methods). Libraries were completed
using the Ion Ampliseq Library Kit (see Supplementary Methods). The libraries
were subjected to emulsion PCR, and prepared for sequencing using the Life
Technologies Ion Chef and the Ion PI IC 200 Kit (Life Technologies). Up to
seven different barcoded libraries were loaded onto one Ion PI v2 BC chip to
obtain appropriate coverage. Sequencing was carried out using a Life
Technologies Ion Proton Next-generation sequencer (Supplementary Fig. 1).
Each sample in our study was sequenced to at least 2500× coverage, with a
Fig. 4 Longitudinal allele frequency tracking of ctDNA mutations. Somatic mutations were first identified in the primary tumor. These
mutations were then searched for in matched plasma samples. ctDNA mutations were identified in four patients at varying allele frequencies.
From patient 146-0005(a) and patient 146-0013(b), the increasing allele frequency of ctDNA was observed before clinically recurrence was
diagnosed. Patient 146-0102(c) and patient 146-0112(d) had only one timepoint plasma sample available, and we were able to detect the
ctDNA before clinical recurrence as well. The lead-time range was 0.07 to 8.87 months
Fig. 5 Kaplan–Meier plot: disease-free survival stratified by presence
of tumor mutation in plasma. Four patients from this study who had
mutation identified from plasma samples relapsed rapidly (0.3, 4.0,
5.3, and 8.9 months). The yellow line represents patients with
detectable ctDNA in plasma. The blue line represents patients with
no detectable ctDNA in plasma.The difference in median DFS
between patients with detectable ctDNA vs. those without was
statistically significant (p< 0.0001, median DFS: 4.6 mos. vs. NR; HR
= 12.6, 95% CI: 3.06-52.2)
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median coverage of 6071× (range 2559×–13995×). Coverage details and allele
frequencies of all observed mutations are detailed in Supplementary Table 1.
Bioinformatics analysis
Each sequencing run produced approximately 56–89 million reads. Reads
underwent primary analysis using the Torrent Suite v4.2.1, which includes
quality control, read trimming, and mapping to the human genome (hg19).
Variant calling was performed using the Torrent Variant Caller v4.2.1.0.
Somatic mutations were identified by comparing variants observed in the
tumor sample that were not present in a matched blood sample. Identified
somatic variants were then searched for in the plasma DNA sequencing
using the Torrent Variant Caller. We also manually inspected called variants
using the integrative genomics viewer27, 28 to confirm the presence of
variants and to rule out false positives.
Statistical analysis
Clinical follow-up data was provided by the trial contract research
organization: Hoosier Cancer Research Network. The median follow-up for
DFS for the entire trial was 24 months. DFS analysis was performed using Cox
regression (IBM SPSS Statistics version 24) and plotted using the
Kaplan–Meier method (Graphpad Prism, GraphPad Software, Inc.). In
univariate Cox regression analysis, the detection of ctDNA was significantly
associated with inferior DFS (see Results). In multivariate Cox regression,
when adding RCB and number of positive lymph nodes as covariates, the
detection of ctDNA was independently associated with DFS (see Results).
Age, race, tumor grade, and Eastern Cooperative Oncology Group (ECOG)
performance status were not associated with DFS, and not used as covariates.
Data availability
The detailed sequencing results of coverage numbers, allele frequency,
and tumor cellularity are available in Supplementary Table 1.
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